Aileron Therapeutics is a biotechnology company focused on the development of innovative drug therapies that leverage its proprietary platform for the design of stapled peptides
These therapies are aimed at treating a range of serious diseases, including cancer and other conditions characterized by protein-protein interactions. By stabilizing the structure of peptides, the company enhances their ability to engage specific biological targets, with the goal of improving patient outcomes through more effective treatments. Aileron's commitment to advancing therapeutic options is supported by robust research and collaborations within the scientific community.
Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to enhance lung function in IPF patients.
Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated
AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:
Aileron Therapeutics (NASDAQALRN) is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. The company has announced the closing of its underwritten registered direct offering priced at-the-market under Nasdaq rules of 4,273,505 shares of its common stock and accompanying warrants to purchase an aggregate of 4,273,505 shares of common stock. Aileron secured aggregate gross proceeds of approximately $20 million, before deducting underwriting discounts and commissions and other offering expenses and excluding any proceeds that may be received from exercise of the warrants. Titan Partners Group, a division of American Capital Partners, acted as sole book-running manager for the offering.
Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering
Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering
Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker indicative of epithelial health, suggesting potential therapeutic effect
Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of 2024
Topline results from Phase 1b study of LTI-03, Aileron’s novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected in the second quarter of 2024
Shares of United Parcel Service, Inc. (NYSEUPS) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter sales results and issued FY24 sales
Shares of Quanex Building Products Corporation (NYSENX) moved lower during Friday’s session after the company reported fourth-quarter financial results. Quanex Building Products shares fell 10.7% to $30.95 on Friday.
Shares of Getaround, Inc. (NYSEGETR) rose sharply in pre-market trading after the company reported a year-over-year increase in third-quarter financial results.
